Scholar Rock ($4.6B) has a validated drug stuck behind a broken factory. The 10-K tells a clean story: Phase 3 hit (p=0.0192), FDA has no scientific objection, the only barrier is a third-party fill-finish facility's quality failures. The question isn't whether apitegromab works — it does. The question is when Catalent Indiana fixes its manufacturing, and nobody outside the facility knows the answer.

The Drug

Apitegromab is a monoclonal antibody that blocks myostatin activation in skeletal muscle. Phase 3 SAPPHIRE hit its primary endpoint: +1.8 HFMSE points versus placebo in SMA patients aged 2-12 (p=0.0192), with 30.4% of patients achieving ≥3-point responses versus 12.5% placebo (OR 3.0). Zero drug-related serious adverse events across 4+ years of safety data. First and only Phase 3-positive myostatin inhibitor in SMA.

The modest effect size (+1.8 on a 66-point scale) will face payer scrutiny at orphan pricing ($200-500K+/year). But the responder analysis is the more relevant metric — nearly a third of treated patients achieved clinically meaningful improvement versus one-eighth on placebo. In a progressive disease with no approved muscle-directed therapy, that's a real signal.

The Factory Problem

The BLA was filed January 2025 and received Priority Review. In July 2025, FDA inspected the fill-finish facility — Catalent Indiana LLC in Bloomington, now owned by Novo Nordisk — and found six observations: hair contamination, pest infestations, equipment failures, investigation gaps. The facility was classified OAI (most serious) in October and received a Warning Letter in November. SRRK's CRL in September cited only this facility; the drug substance manufacturer and all clinical data are clean.

The remediation cadence is encouraging. Novo responded to the warning letter in December. FDA held an early Q1 2026 meeting with "no additional requests." FDA sent a field team to the site in late February — again, no additional requests. Novo resumed routine manufacturing. But OAI facilities require formal reinspection before warning letters are lifted. That reinspection hasn't been scheduled.

Three CMC-only CRL comps frame the base rate:

• RCKT (KRESLADI): CMC info request CRL June 2024. Resubmission October 2025. PDUFA March 28, 2026 — resolving in 19 days. Simpler issue (information, not facility failure). 16 months CRL→PDUFA.
• RARE (UX111): CMC CRL July 2025. CEO said "readily addressable." Resubmission January 2026. Then FDA issued an Incomplete Response Letter in February requesting MORE documentation. CMC CRLs iterate.
• Regeneron (Eylea HD): Same Catalent Bloomington facility. CRL October 2025. Regeneron switched to an alternate manufacturer. Big pharma can work around a bad facility; small biotechs can't easily.

RARE is the cautionary tale. "Constructive" FDA engagement doesn't guarantee smooth resubmission. But SRRK's situation differs: Novo Nordisk has $16.5B invested in this facility and serves "the vast majority of top biopharmaceutical companies." FDA has practical incentive to resolve this — the facility is systemically important. CURE SMA attended the Type A meeting, adding patient advocacy pressure. And SRRK is qualifying a second US fill-finish facility (sBLA planned later 2026) as insurance.

The Competitive Moat

This is the strongest finding from the trawl. Biohaven's taldefgrobep alfa — the only other anti-myostatin antibody in Phase 3 for SMA — FAILED its primary endpoint in the RESILIENT trial. Biohaven is pivoting to obesity.

Apitegromab now has a confirmed 2-3 year first-mover monopoly in validated anti-myostatin SMA therapy. Roche's GYM329 is still in Phase 2/3 but restricted to risdiplam-only combination (Roche's own SMN drug), which limits its addressable market to one-third of SMA patients. NMD Pharma's NMD670 is Phase 2, different mechanism entirely, data not until November 2026.

The addressable market is 35,000 patients globally already on SMN-targeted therapy (nusinersen, risdiplam, onasemnogene), 95% of whom still experience progressive muscle weakness. Apitegromab is studied across ALL background SMN therapies — broader addressable market than any competitor.

The Cash Clock

$367.6M in liquidity at year-end 2025. Burning $300M/year — $25M per month — with zero revenue. That's roughly 15 months of runway. Management says "into 2027."

G&A exploded 161% year-over-year ($176M versus $67M) as the company pre-built commercial infrastructure: ≈50 US field professionals hired, European commercial organization started, entire C-suite replaced. This is either management conviction in imminent approval or poor capital discipline before knowing when (or if) approval comes. The answer depends entirely on Factor 1.

Blue Owl's credit facility is cleverly structured: $100M initial term loan + $100M DDTL-1 (expires March 31, 2026 — likely drawing now) + $150M DDTL-2 available ONLY after FDA approval. Blue Owl is making an event-driven credit bet — confident enough in eventual approval to commit $150M post-event, but not confident enough to fund the wait. The DDTL-2 structure tells you what sophisticated lenders think: this drug gets approved, eventually.

If approval comes by Q4 2026, cash is adequate. If it drags into 2027, SRRK needs a dilutive raise — probably at $25-35, destroying 30-40% of current equity.

What the Options Market Sees

The options tell a more nuanced story than 100% analyst buy consensus suggests. Near-term March options are wildly bullish (P/C ratio 0.08). But the April expiration flips bearish: P/C ratio 2.02, with 3,184 contracts in $35 puts — 37% of ALL April open interest in a single strike. That's ≈$17M notional of downside protection. Someone large is hedging through mid-April, possibly against RCKT PDUFA read-through (March 28) or adverse facility news.

January 2027 options price a ±49% move from current ($23-67 range). Unusual deep OTM put volume at $15-20 strikes — 5x OI ratio at $15 — prices roughly 10-15% catastrophic probability. This aligns with our factor decomposition.

Call IV is elevated 11-17% above put IV across all expirations, which is unusual. Normally crash hedging makes puts richer. Elevated call IV reflects demand for upside exposure on the squeeze potential — 25.7% short float with 15.5 days to cover.

Factor Decomposition

Eight independent factors. Edge only in one.

55% of thesis variance sits in two factors where we have zero edge: CMC remediation timeline and payer acceptance. Another 25% is mechanically dependent on CMC timing. The 10% where we have mild edge — competitive moat — is the wrong factor. It supports the thesis but doesn't resolve the binary.

Insider Activity

New C-suite received large equity awards in February (CEO: 128K shares, ≈$5.8M). Four officers immediately sold portions totaling $1.8M. Zero open market purchases by any insider.

This is typical for new management — tax withholding and diversification on comp awards. But compare to Biohaven, where the CEO put $5M of his own money in and the founder put in $25M. That's conviction. SRRK insiders are compensated. They aren't invested.

The New Risk Factors

Two additions in the 2026 10-K that didn't exist in prior filings:

1. FDA DOGE disruption: "Changes or disruptions at the FDA caused by funding cuts, personnel reductions, substantial changes in leadership and policy... could prevent these agencies from performing functions... including the timely review and potential approval of our BLA when resubmitted." A BLA resubmission requires active reviewer engagement. Fewer reviewers = longer queue.

2. EU reimbursement: Germany HTA/AMNOG pricing negotiation explicitly flagged. Not boilerplate — this is a company that just hired European commercial staff and now warns that EU payers may not cover the drug.

Conclusion

SRRK is a clean thesis gated by a dirty factory. The drug works. The competitor failed. The monopoly is confirmed. If Catalent Bloomington clears FDA reinspection, this stock re-rates to $70-90. If it doesn't clear in 2026, the cash clock forces a dilutive raise and the stock trades $25-35.

The problem is that the gating factor — when a third-party manufacturing facility satisfies FDA cGMP requirements — is entirely opaque from public data. We can't assess it. 16 analysts can't assess it. The shorts can't assess it. Everyone is making the same bet with the same information gap.

At $4.6B market cap with 100% analyst buy consensus, this is a consensus trade on the drug and a coin flip on the facility. Edge exists only in the competitive moat (Biohaven failure), which accounts for 10% of thesis variance. The other 90% is either opaque (CMC, payer) or dependent on the opaque factor (cash, FDA review).

The RCKT PDUFA on March 28 is the next cross-ticker read-through. If KRESLADI is approved (CMC-only CRL resolved), it validates the pattern and provides mild positive sentiment for SRRK — though RCKT's issue was simpler (information request versus facility Warning Letter). If rejected, negative read-through across all CMC CRL plays.

Epistemic state: Doorway. 60% Pattern A (CRL resolves 2026, approval, $70-90). 40% Pattern B (CRL drags, dilution, $25-35). Catalyst: Catalent Bloomington FDA reinspection clearance. No edge on when that happens.

LR = 1.1. Biohaven failure slightly strengthens competitive moat versus consensus, but the gating factor is priced correctly as uncertain. Analysis confirms what the market already debates. No information advantage.

Evidence